{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:51:22Z","timestamp":1774435882536,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jneuroim.2025.578804","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:55:50Z","timestamp":1762764950000},"page":"578804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Autoimmune encephalitis following bevacizumab therapy in ovarian carcinoma: A case report and review"],"prefix":"10.1016","volume":"410","author":[{"given":"Beng\u00fcl Fatma","family":"G\u00f6lge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cansu","family":"Sar\u0131kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan Aykut","family":"Bing\u00f6l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berrin","family":"Aktekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gazanfer","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jneuroim.2025.578804_bb0005","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010011","article-title":"A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy","volume":"97","author":"Attademo","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578804_bb0010","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.jfma.2023.07.019","article-title":"Atezolizumab-induced encephalitis with subdural hemorrhage and subarachnoid hemorrhage in a patient with hepatocellular carcinoma","volume":"122","author":"Chao","year":"2023","journal-title":"J. Formos. Med. Assoc."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578804_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1474-4422(23)00083-2","article-title":"Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease","volume":"22","author":"Dalmau","year":"2023","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578804_bb0020","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.3390\/cancers16213571","article-title":"Cancer therapy-induced encephalitis","volume":"16","author":"Desbaillets","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578804_bb0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1078155215611048","article-title":"Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature","volume":"22","author":"Ery\u0131lmaz","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jneuroim.2025.578804_bb0030","article-title":"Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis","volume":"16","author":"Fang","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578804_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200155","article-title":"Autoimmune encephalitis consensus criteria: lessons learned from real-world practice","volume":"13","author":"Gelfand","year":"2023","journal-title":"Neurol Clin Pract."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578804_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-251277","article-title":"Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapy","volume":"16","author":"Giucca","year":"2023","journal-title":"BMJ Case Rep."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578804_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"16","key":"10.1016\/j.jneuroim.2025.578804_bb0050","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.2169\/internalmedicine.0284-17","article-title":"Posterior reversible encephalopathy syndrome after a variety of combined chemotherapies containing bevacizumab for metastatic Colon Cancer","volume":"57","author":"Katada","year":"2018","journal-title":"Intern. Med."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578804_bb0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic oncology group study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jneuroim.2025.578804_bb0060","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1200\/EDBK_239007","article-title":"The evolving landscape of chemotherapy in newly diagnosed advanced epithelial ovarian cancer","volume":"39","author":"Monk","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578804_bb0065","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","article-title":"Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review","volume":"97","author":"Nersesjan","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578804_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200151","article-title":"Autoimmune encephalitis criteria in clinical practice","volume":"13","author":"Orozco","year":"2023","journal-title":"Neurol Clin Pract."},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578804_bb0075","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2169\/internalmedicine.4321-24","article-title":"Patient with atezolizumab-induced encephalitis in hepatocellular carcinoma","volume":"64","author":"Otomo","year":"2025","journal-title":"Intern. Med."},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578804_bb0080","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.jneuroim.2025.578804_bb0085","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026377","article-title":"Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: case report and literature review","volume":"100","author":"\u00d6zdirik","year":"2021","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578804_bb0090","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/02656736.2018.1503346","article-title":"Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"35","author":"Paris","year":"2018","journal-title":"Int. J. Hyperthermia"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578804_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00432-024-05918-9","article-title":"Atezolizumab- and bevacizumab-induced encephalitis in a patient with advanced hepatocellular carcinoma: a case report and literature review","volume":"150","author":"Sagong","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.jneuroim.2025.578804_bb0100","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2169\/internalmedicine.8919-21","article-title":"Atezolizumab-induced encephalitis in a patient with hepatocellular carcinoma: a case report and literature review","volume":"61","author":"Satake","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.jneuroim.2025.578804_bb0105","article-title":"Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies","volume":"13","author":"Zhang","year":"2025","journal-title":"Front. Bioeng. Biotechnol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T22:09:22Z","timestamp":1764886162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825002851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"alternative-id":["S0165572825002851"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578804","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune encephalitis following bevacizumab therapy in ovarian carcinoma: A case report and review","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578804"}}